The clinical management of this tumor type has profoundly changed with the implementation of prostate specific antigen (PSA)-based screening, minimally invasive robotic surgery, and new-generation androgen synthesis and signaling inhibitors [2, 3]. This evidence concerns the gene KLK3 and neoplasm.